Three-year results of a randomized prospective trial of methionyl human growth hormone and oxandrolone in Turner syndrome

• Published in: The Journal of pediatrics Vol. 113; no. 2; pp. 393 - 400
• Main Authors: Rosenfeld, Ron G., Hintz, Raymond L., Johanson, Ann J., Sherman, Barry, Brasel, Jo Anne, Burstein, Stephen, Chernausek, Steven, Compton, Peter, Frane, James, Gotlin, Ronald W., Kuntze, Joyce, Lippe, Barbara M., Mahoney, Patrick C., Moore, Wayne V., New, Maria I., Saenger, Paul, Sybert, Virginia
• Format: Journal Article
• Language: English
• Published: New York, NY Mosby, Inc 01.08.1988; Elsevier
• Subjects: Biological and medical sciences; Body Height; Child; Child, Preschool; Drug Therapy, Combination; Female; Growth - drug effects; Growth Hormone - administration & dosage; Growth Hormone - analogs & derivatives; Growth Hormone - therapeutic use; Hormones - administration & dosage; Hormones - therapeutic use; Hormones. Endocrine system; Human Growth Hormone; Humans; Medical sciences; Oxandrolone - administration & dosage; Oxandrolone - therapeutic use; Pharmacology. Drug treatments; Prospective Studies; Random Allocation; Turner Syndrome - drug therapy; Human; Dysgenesia; Statistical analysis; STH; Controlled therapeutic trial; Administration schedule; Turner syndrome; Long term; Protein hormone; Chemotherapy; Oxandrolone; Treatment; Adenohypophyseal hormone; Gonad; Analog; Child
• ISSN: 0022-3476; 1097-6833
• DOI: 10.1016/S0022-3476(88)80290-7

Seventy girls with Turner syndrome, 4 to 12 years of age, participated in a prospective, randomized study to determine the effects on growth of methionyl human growth hormone (met-hGH) or oxandrolone. Subjects were randomly assigned to receive either no treatment (control) or met-hGH (0.125 mg/kg three times per week), oxandrolone (0.125 mg/kg/day), or combination met-hGH plus oxandrolone. At the end of an initial period of 12 to 20 months, patients in the original control and oxandrolone groups were given combination met-hGH plus oxandrolone. At that time the dosage of oxandrolone was lowered to 0.0625 mg/kg/day. Sixty-five subjects have now completed the first 3 years of the study. Compared with the control growth rate for year 1 (3.8 cm/yr), significant increases in growth rate were seen in all 3 years of combination therapy (9.8, 7.4, and 6.1 cm/yr, respectively) and in the first 2 years of treatment with met-hGH alone (6.6, 5.4, and 4.6 cm/yr). When growth velocity was expressed as standard deviation for age in girls with Turner syndrome, significant increases relative to the control group for year 1(−0.1 SD) were seen in all three years of both combination therapy and met-hGH alone (combination, +6.6, +4.3, +3.0 SD; met-hGH, +3.1, +2.0, +1.4 SD). After 3 years of treatment, predicted adult height by the method of Bayley-Pinneau increased 4.5 cm in the met-hGH group and 8.2 cm in the combination group.